Citigroup Downgrades Boston Scientific to Neutral, Lowers Price Target to $50

Benzinga Newsdesk www.benzinga.com Negative 90.3%

Neg 90.3% Neu 0% Pos 0%

Citigroup analyst Joanne Wuensch downgrades Boston Scientific (NYSE:BSX) from Buy to Neutral and lowers the price target from $57 to $50.